NCT04926506 is a NA clinical trial of Xiyanping injection in Acute Bronchitis in Children, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd..

Who is sponsoring NCT04926506?

NCT04926506 is sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd..

What drugs are being tested in NCT04926506?

Interventions in NCT04926506: Xiyanping injection.

What condition does NCT04926506 study?

NCT04926506 studies Acute Bronchitis in Children.

Is NCT04926506 still recruiting?

NCT04926506 is currently status unknown. Last updated 4 October 2021.

Last reviewed 2021-10-04 · How we verify

NCT04926506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children

Status unknown NA Last updated 4 October 2021

What this trial tests

NA trial testing Xiyanping injection in Acute Bronchitis in Children in 80 participants. Status unknown.

Timeline

8 October 2021

Primary endpoint
21 September 2022

30 December 2022

Quick facts

Lead sponsor	Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	8 October 2021
Primary completion	21 September 2022
Estimated completion	30 December 2022

Drugs / interventions tested

Xiyanping injection — full drug profile →

Conditions studied

Acute Bronchitis in Children — all drugs for Acute Bronchitis in Children →

Sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd. — full company profile →

Who can join

Adults 1 to 6, any sex, with Acute Bronchitis in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Any pathogen that causes an upper respiratory tract infection can cause bronchitis.The primary pathogen is virus. On the basis of virus infection, pathogenic bacteria may cause secondary infection or co-infection。Xiyanping injection is mainly used in the treatment of bronchitis by intravenous injection。

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Xiyanping injection

Trials testing the same drug.

NCT04275388 — Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia · unknown

Other Jiangxi Qingfeng Pharmaceutical Co. Ltd. trials

Trials by the same sponsor.

NCT06574503 — Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza · Phase 3 · recruiting
NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
NCT06678542 — Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects · Phase 1 · completed
NCT06643156 — Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension · Phase 1 · completed
NCT05814926 — GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04926506 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Last refreshed: 4 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing